Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

• Conditions: Pancreatic Cancer

• Registration Number: NCT02550847
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Detailed Description

The results of MR/PET will be compared prospectively to dedicated MDCT or MR imaging, pathologic results, and clinical outcomes to assess the value of MR/PET in pancreatic cancers.

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2015-09-08
• Study First Submitted QC: 2015-09-15
• Study First Posted: 2015-09-16
• Status Verified: 2016-04
• Primary Completion: 2016-04
• Last Update Submitted: 2016-04-12
• Last Update Posted: 2016-04-14
• Study Completion: 2016-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Diagnosed as pancreatic cancer
2. Between 20~90 years old
3. ECOG 0-2
4. Normal renal function
5. Measurable tumor size (>1cm)

Exclusion Criteria

1. Contraindication for MRI exam
2. Claustrophobia
3. Renal insufficiency
4. Other malignancy
5. Pregnancy and lactating women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The tumor recurrence rate after operation at 6 months	6 months

Secondary Outcome Measures

Name	Time	Method
The overall survival after operation at 6 months	6 months

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan